Viking Therapeutics Stock Takes a Hit as Weight-Loss Pill Trial Shows High Dropout
Viking Therapeutics (VKTX) experienced a significant drop in its stock value, falling by over 40% following the disappointing results from its phase 2 weight-loss pill trial. The company’s stock plummeted by 41.68% on a Tuesday, reflecting investor concern over the high dropout rate in the study and the associated gastrointestinal side effects reported by many participants. Despite promising weight-loss results, Viking’s trial exposed serious challenges that have raised questions about the pill’s long-term viability and market potential.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
